Prudential Financial Inc Mirati Therapeutics, Inc. Transaction History

Prudential Financial Inc

$70.5 Billion
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $1.92 Million - $3.83 Million	-25,369 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $513,518 - $740,228	3,890 Added 18.11%	25,369 $3.84 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $945,125 - $1.27 Million	7,153 Added 49.93%	21,479 $3.8 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $506,880 - $632,649	3,520 Added 32.57%	14,326 $2.31 Million
Q1 2021 May 12, 2021	BUY	$158.92 - $221.61 $1.2 Million - $1.67 Million	7,542 Added 231.07%	10,806 $1.85 Million

Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $455,198 - $674,918	2,809 Added 617.36%	3,264 $717,000
Q3 2020 Aug 05, 2021	SELL	$113.26 - $167.27 $226,293 - $334,205	-1,998 Reduced 81.45%	455 $76,000
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $273,409 - $403,789	2,414 Added 6189.74%	2,453 $407,000
Q2 2020 Aug 05, 2021	SELL	$72.01 - $120.39 $1.31 Million - $2.19 Million	-18,204 Reduced 99.79%	39 $4,000
Q2 2020 Aug 12, 2020	BUY	$72.01 - $120.39 $1.31 Million - $2.19 Million	18,159 Added 21617.86%	18,243 $2.08 Million
Q1 2020 Aug 05, 2021	SELL	$69.78 - $116.21 $1.59 Million - $2.64 Million	-22,721 Reduced 99.63%	84 $6,000
Q1 2020 May 12, 2020	BUY	$69.78 - $116.21 $1.58 Million - $2.64 Million	22,707 Added 23170.41%	22,805 $1.75 Million
Q4 2019 Aug 05, 2021	SELL	$70.76 - $128.86 $1.63 Million - $2.98 Million	-23,097 Reduced 99.58%	98 $13,000
Q4 2019 Feb 11, 2020	BUY	$70.76 - $128.86 $1.5 Million - $2.74 Million	21,225 Added 1077.41%	23,195 $2.99 Million
Q2 2019 Aug 08, 2019	BUY	$59.49 - $104.71 $117,195 - $206,278	1,970 New	1,970 $0

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.

Account